Study of EF-009 for pancreatic cancer that may not be removable
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests EF-009, a study medicine, in adults with pancreatic cancer that doctors consider “borderline resectable” or “unresectable.” The goal is to see how safe it is and how well it works for this situation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 18 or older.
- You must have confirmed pancreatic cancer from a scan plus a tissue or cell test (biopsy/pathology).
- Your tumor must be considered borderline resectable or unresectable by the study doctors, with no distant metastases.
- Your general health must be fairly good (ECOG 0–1) and you must be able to sign consent.
- Recent lab tests must be adequate (blood counts, liver, kidneys, and clotting), and you must have recovered from side effects of prior treatment.
- If you can get pregnant or get someone pregnant, you must use reliable birth control during the study and for 4 weeks after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial is testing a new endoscopic (from inside the stomach) approach for pancreatic ductal adenocarcinoma that is locally advanced and cannot be removed with surgery. It may help some people who have already tried first chemotherapy and still have a tumor confined to the pancreas area (no spread).
This trial tests a new immune cell therapy (EGFRBi armed PBMC) for people with advanced pancreatic cancer that can't be removed by surgery. It aims to see if this treatment can help control the cancer after you've already tried at least one type of chemotherapy and your disease is stable or better.
This trial tests a new treatment, PTM-101, placed during a laparoscopy procedure for people with pancreatic cancer that can be removed with surgery. It aims to see if adding this treatment before standard chemotherapy helps improve outcomes.
This early-stage trial tests a new drug called ES502 for patients with advanced cancers (including pancreatic cancer) that have a specific genetic mutation and certain immune markers. The study aims to find the right dose and see if it helps shrink tumors.
This study uses small pancreatic cancer samples grown in the lab to understand which treatments may work best for people with pancreatic cancer. It may help researchers better “profile” tumors so standard care can be matched to the most effective options.
This Phase 2 trial tests a chemotherapy plan given before surgery (called “neoadjuvant” treatment) for people with pancreatic adenocarcinoma that looks resectable or borderline resectable on scans. The goal is to see how well this adaptive chemotherapy approach works and whether it can improve outcomes before an operation.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.